{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T14:07:20Z","timestamp":1774879640808,"version":"3.50.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Supplement 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1097\/cco.0b013e32835de8ee","type":"journal-article","created":{"date-parts":[[2013,2,6]],"date-time":"2013-02-06T15:20:08Z","timestamp":1360164008000},"page":"S1-S12","source":"Crossref","is-referenced-by-count":17,"title":["Temsirolimus in the treatment of mantle cell lymphoma"],"prefix":"10.1097","volume":"25","author":[{"given":"Krimo","family":"Bouabdallah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Ribrag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Terriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Charles","family":"Soria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Delarue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210128","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.semcancer.2011.09.010","article-title":"Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.","volume":"21","author":"Smedby","year":"2011","journal-title":"Semin Cancer Biol"},{"key":"R3-1-20210128","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.2165\/11594630-000000000-00000","article-title":"Current status of targeted therapies for mantle cell lymphoma.","volume":"71","author":"Chang","year":"2011","journal-title":"Drugs"},{"key":"R4-1-20210128","first-page":"167","article-title":"Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma.","volume":"3","author":"Samad","year":"2010","journal-title":"Onco Targets Ther"},{"key":"R5-1-20210128","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma.","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"R7-1-20210128","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of mTOR inhibitors as anticancer agents.","volume":"5","author":"Faivre","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"R8-1-20210128","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"key":"R9-1-20210128","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigators choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"R11-1-20210128","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/cncr.23580","article-title":"Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.","volume":"113","author":"Ansell","year":"2008","journal-title":"Cancer"},{"key":"R12-1-20210128","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1586\/ehm.09.57","article-title":"Temsirolimus for the treatment of mantle cell lymphoma.","volume":"2","author":"Hess","year":"2009","journal-title":"Expert Rev Hematol"},{"key":"R14-1-20210128","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet Oncol"},{"key":"R16-1-20210128","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"R17-1-20210128","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1200\/JCO.2010.29.2201","article-title":"American Society of Clinical OncologyAmerican Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.","volume":"28","author":"Rizzo","year":"2010","journal-title":"J Clin Oncol"},{"key":"R18-1-20210128","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000329902","article-title":"Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors.","volume":"223","author":"De Masson","year":"2011","journal-title":"Dermatology"},{"key":"R19-1-20210128","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1200\/JCO.2010.29.2813","article-title":"Temsirolimus has activity in nonmantle cell non-Hodgkins lymphoma subtypes: the University of Chicago phase II consortium.","volume":"28","author":"Smith","year":"2010","journal-title":"J Clin Oncol"},{"key":"R20-1-20210128","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1600-6143.2008.02272.x","article-title":"Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients.","volume":"8","author":"Kasiske","year":"2008","journal-title":"Am J Transplant"},{"key":"R21-1-20210128","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1097\/00007890-200110150-00011","article-title":"Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients.","volume":"72","author":"Hoogeveen","year":"2001","journal-title":"Transplantation"},{"key":"R22-1-20210128","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1034\/j.1600-6143.2003.00094.x","article-title":"Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice.","volume":"3","author":"Elloso","year":"2003","journal-title":"Am J Transplant"},{"key":"R23-1-20210128","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.ejca.2006.03.015","article-title":"Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus.","volume":"42","author":"Duran","year":"2006","journal-title":"Eur J Cancer"},{"key":"R24-1-20210128","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4137\/CMO.S4482","article-title":"Renal cell carcinoma: focus on safety and efficacy of temsirolimus.","volume":"4","author":"Hadoux","year":"2010","journal-title":"Clin Med Insights Oncol"},{"key":"R25-1-20210128","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1378\/chest.07-0851","article-title":"Pulmonary complications of novel antineoplastic agents for solid tumors.","volume":"133","author":"Vahid","year":"2008","journal-title":"Chest"},{"key":"R26-1-20210128","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1200\/JCO.2010.29.2235","article-title":"Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.","volume":"29","author":"Maroto","year":"2011","journal-title":"J Clin Oncol"},{"key":"R28-1-20210128","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.2146\/ajhp100020","article-title":"Mammalian target of rapamycin: biological function and target for novel anticancer agents.","volume":"67","author":"Borders","year":"2010","journal-title":"Am J Health Syst Pharm"},{"key":"R29-1-20210128","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.eururo.2007.11.037","article-title":"Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.","volume":"53","author":"Bhojani","year":"2008","journal-title":"Eur Urol"},{"key":"R30-1-20210128","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/annonc\/mdn066","article-title":"Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features.","volume":"19","author":"Bellmunt","year":"2008","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"R32-1-20210128","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1634\/theoncologist.12-S1-22","article-title":"Mechanisms of cancer-related fatigue.","volume":"12","author":"Ryan","year":"2007","journal-title":"Oncologist"},{"key":"R33-1-20210128","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.ejca.2004.06.019","article-title":"The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.","volume":"40","author":"Ludwig","year":"2004","journal-title":"Eur J Cancer"},{"key":"R34-1-20210128","first-page":"439","article-title":"Anemia in lung cancer patients.","volume":"92","author":"Meric","year":"2005","journal-title":"Bull Cancer"},{"key":"R35-1-20210128","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.2165\/11204940-000000000-00000","article-title":"Temsirolimus: in relapsed andor refractory mantle cell lymphoma.","volume":"70","author":"Hoy","year":"2010","journal-title":"Drugs"},{"key":"R36-1-20210128","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/00002018-199512040-00004","article-title":"Prevention and management of extravasation of cytotoxic drugs.","volume":"12","author":"Bertelli","year":"1995","journal-title":"Drug Saf"},{"key":"R38-1-20210128","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1093\/annonc\/mdq766","article-title":"Sexual life of male patients with advanced renal cancer treated with angiogenesis inhibitors.","volume":"22","author":"Bessede","year":"2011","journal-title":"Ann Oncol"},{"key":"R39-1-20210128","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1432-2277.2006.00423.x","article-title":"Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview.","volume":"20","author":"Huyghe","year":"2007","journal-title":"Transpl Int"},{"key":"R40-1-20210128","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1046\/j.1600-6135.2003.00279.x","article-title":"Testosterone concentrations and sirolimus in male renal transplant patients.","volume":"4","author":"Fritsche","year":"2004","journal-title":"Am J Transplant"},{"key":"R41-1-20210128","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1600-6143.2004.00456.x","article-title":"Sirolimus impairs gonadal function in heart transplant recipients.","volume":"4","author":"Kaczmarek","year":"2004","journal-title":"Am J Transplant"},{"key":"R42-1-20210128","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1016\/j.transproceed.2008.06.015","article-title":"Sirolimus used during pregnancy in a living related renal transplant recipient: a case report.","volume":"40","author":"Chu","year":"2008","journal-title":"Transplant Proc"},{"key":"R43-1-20210128","first-page":"602","article-title":"Psychiatric disorders: targeting a PI3K subunit in schizophrenia.","volume":"11","author":"Harrison","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"R44-1-20210128","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000322145","article-title":"Alterations in phosphatidylinositol 3-kinase activity and PTEN phosphatase in the prefrontal cortex of depressed suicide victims.","volume":"63","author":"Karege","year":"2011","journal-title":"Neuropsychobiology"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0b013e32835de8ee","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T19:38:56Z","timestamp":1621885136000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201303002-00001"}},"subtitle":["frequency and management of adverse effects"],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":36,"journal-issue":{"issue":"Supplement 2","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e32835de8ee","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}